Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource-constrained setting
| Image |  |
|---|---|
| Description | scientific article published on 12 August 2020 |
| Author/s |
author: CS Chim Yok-Lam Kwong |
| Publication date | August 12, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |